Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 17, 2020 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of Preliminary Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Refractory Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

36% ORR and 64% DCR (RECIST 1.1)PV-10-induced, tumor-specific restoration of T cell functionData compare favorably to approved and investigational therapies for patient population KNOXVILLE, TN,...
September 17, 2020 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Presentation of 2-Year Landmark Data from Combination Therapy Trial of PV-10® and KEYTRUDA® for Checkpoint-Naïve Advanced Cutaneous Melanoma at ESMO Virtual Congress 2020

62% 2-year OS; median OS not reachedStable, non-overlapping safety profileClinical synergy between PV-10 and immune checkpoint blockadeData compare favorably to approved therapies for patient...
September 09, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...